| Project/Area Number |
20590699
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
General internal medicine (including Psychosomatic medicine)
|
|---|
| Research Institution | Shimane University |
|---|
Principal Investigator |
YAMAGUCHI TORU Shimane University, 医学部, 准教授 (00239899)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
YAMAMOTO Masahiro 島根大学, 医学部, 助教 (50346392)
KANAZAWA Ippei 島根大学, 医学部, 助教 (50452553)
|
|---|
| Project Period (FY) |
2008 – 2010
|
| Project Status |
Completed (Fiscal Year 2010)
|
| Budget Amount *help |
¥3,900,000 (Direct Cost: ¥3,000,000、Indirect Cost: ¥900,000)
Fiscal Year 2010: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
Fiscal Year 2009: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2008: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
|
|---|
| Keywords | 老年医学 / 糖尿病 / 骨粗鬆症 / 椎体骨折 / 骨芽細胞 / メバロン酸経路 / 2型糖尿病 / IGF-I / osteocalcin / osteoclcin / 動脈硬化 / adiponectin / AMP Kinase / Rho-kinase / Bone morphogenetic protein-2 |
|---|
| Research Abstract |
We showed that inhibition of the mevalonate pathway by AICAR, Metformin, and Fasdiul is involved in osteoblast differentiation, suggesting that these drugs for diabetes mellitus and vascular diseases are also effective for enhancement in bone formation. In clinical studies, we found that bone mineral density is not useful for assessing the risk of vertebral fractures in patients with type 2 diabetes. Serum levels of pentosidine, esRAGE, and IGF-I could be surrogate markers for its assessment in replace for the insensitiveness of BMD. We also found that serum osteocalcin level, an osteoblast-specific protein, is inversely associated with diabetic and atherosclerotic indices, suggesting the existence of common pathogenesis between bone and glucose metabolism through osteocalcin action.
|
